735 related articles for article (PubMed ID: 28406713)
1. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
[TBL] [Abstract][Full Text] [Related]
2. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
4. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
[TBL] [Abstract][Full Text] [Related]
5. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
7. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
8. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
[No Abstract] [Full Text] [Related]
10. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
12. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
[TBL] [Abstract][Full Text] [Related]
13. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
[TBL] [Abstract][Full Text] [Related]
14. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
15. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
[TBL] [Abstract][Full Text] [Related]
16. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
[TBL] [Abstract][Full Text] [Related]
19. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]